Single-Agent Pemetrexed or Sequential Pemetrexed/Gemcitabine as Front-Line Treatment of Advanced Non-small Cell Lung Cancer in Elderly Patients or Patients Ineligible for Platinum-Based Chemotherapy: A Multicenter, Randomized, Phase II Trial
- 1 March 2007
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 2 (3) , 221-229
- https://doi.org/10.1097/jto.0b013e318031cd62
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week scheduleLung Cancer, 2005
- Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomesLung Cancer, 2005
- Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung CancerClinical Cancer Research, 2004
- Chemotherapy Options for the Elderly Patient with Advanced Non-Small Cell Lung CancerThe Oncologist, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer A multicenter phase II studyLung Cancer, 2000
- Lung cancer in the elderlyEuropean Journal Of Cancer, 1997
- Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institutionEuropean Journal Of Cancer, 1996
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958